Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery

Ching-Li Tseng, Yueh Hsiu Wu, Su Wen Yu, Kai-Chiang Yang, Feng Huei Lin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin FITC-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.

Original languageEnglish
Title of host publicationIFMBE Proceedings
Pages347-350
Number of pages4
Volume25
Edition8
DOIs
Publication statusPublished - 2009
Externally publishedYes
EventWorld Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors - Munich, Germany
Duration: Sep 7 2009Sep 12 2009

Other

OtherWorld Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors
CountryGermany
CityMunich
Period9/7/099/12/09

Fingerprint

Medical nanotechnology
Aerosols
Epidermal Growth Factor Receptor
Gelatin
Nanoparticles
Cisplatin
Toxicity
Pharmaceutical Preparations
Epidermal Growth Factor
Drug Carriers
Chemotherapy
Fluorescein-5-isothiocyanate
Poisons
Tumors
Fluorescence
Ligands
biotinyl epidermal growth factor
Tissue

Keywords

  • Aerosol delivery
  • Cisplatin
  • EGFR
  • Gelatin nanoparticles
  • Tumor targeting

ASJC Scopus subject areas

  • Biomedical Engineering
  • Bioengineering

Cite this

Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery. / Tseng, Ching-Li; Wu, Yueh Hsiu; Yu, Su Wen; Yang, Kai-Chiang; Lin, Feng Huei.

IFMBE Proceedings. Vol. 25 8. ed. 2009. p. 347-350.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Tseng, C-L, Wu, YH, Yu, SW, Yang, K-C & Lin, FH 2009, Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery. in IFMBE Proceedings. 8 edn, vol. 25, pp. 347-350, World Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors, Munich, Germany, 9/7/09. https://doi.org/10.1007/978-3-642-03887-7-100
@inproceedings{d7c3f17b01334207bf026ab3f174c59a,
title = "Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery",
abstract = "Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin FITC-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.",
keywords = "Aerosol delivery, Cisplatin, EGFR, Gelatin nanoparticles, Tumor targeting",
author = "Ching-Li Tseng and Wu, {Yueh Hsiu} and Yu, {Su Wen} and Kai-Chiang Yang and Lin, {Feng Huei}",
year = "2009",
doi = "10.1007/978-3-642-03887-7-100",
language = "English",
isbn = "9783642038860",
volume = "25",
pages = "347--350",
booktitle = "IFMBE Proceedings",
edition = "8",

}

TY - GEN

T1 - Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery

AU - Tseng, Ching-Li

AU - Wu, Yueh Hsiu

AU - Yu, Su Wen

AU - Yang, Kai-Chiang

AU - Lin, Feng Huei

PY - 2009

Y1 - 2009

N2 - Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin FITC-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.

AB - Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin FITC-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.

KW - Aerosol delivery

KW - Cisplatin

KW - EGFR

KW - Gelatin nanoparticles

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=77949903150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949903150&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-03887-7-100

DO - 10.1007/978-3-642-03887-7-100

M3 - Conference contribution

AN - SCOPUS:77949903150

SN - 9783642038860

VL - 25

SP - 347

EP - 350

BT - IFMBE Proceedings

ER -